Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05051631 · ClinicalTrials.gov registry record · NA
BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity
A NA study of Breast Cancer, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 1,071
- Enrollment target
- 1
- Study location
NCT05051631 is a NA study of Breast Cancer that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 1,071 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05051631, a NA study of Breast Cancer, has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,071 participants
- Enrollment target
- 1
- Study location
Study Summary
The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee. The BRAVE Strategy (Breast cancer Risk Assessment - achieVing Equity) study aims to assess the feasibility, reach, acceptability, and appropriateness of select customized strategies to increase uptake of breast cancer risk assessment. The investigators will achieve these aims through a conducting a stepped-wedge trial conducted in 10 healthcare clinics in the state of Tennessee. The primary outcome is the proportion of women age 25-49 having risk assessment. Secondary outcomes include the numbers of 1) women identified as high-risk; 2) pursuing risk-adherent screening; and 3) diagnosed with breast cancer.
Conditions Studied
Interventions
- OTHER Intervention plus 12 months maintenance
- OTHER Intervention plus 10 months maintenance
- OTHER Intervention plus 8 months maintenance
- OTHER Intervention plus 6 months maintenance
- OTHER Intervention plus 4 months maintenance
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,071 participants |
| Start Date | 2022-03-09 |
| Est. Completion | 2024-08-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05051631
The ClinicalTrials.gov registry entry for NCT05051631 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1,071 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Intervention plus 12 months maintenance is the first listed.
NCT05051631 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05051631 about?
NCT05051631 is a clinical study titled "BRAVE Strategy - Breast Cancer Risk Assessment -achieVing Equity". The central goal of this study is to test strategies to implement evidence-based breast cancer risk assessment in healthcare clinics in Tennessee. The BRAVE Strategy (Breast cancer Risk Assessment - achieVing Equity) study aims to assess the feasibility, reach, acceptability, and appropriateness of ...
What is the current status of trial NCT05051631?
This trial is currently completed. It is a NA study. The enrollment target is 1,071 participants. The study started on 2022-03-09. Estimated completion is 2024-08-30.
What conditions does trial NCT05051631 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05051631?
The interventions under investigation include: Intervention plus 12 months maintenance (OTHER), Intervention plus 10 months maintenance (OTHER), Intervention plus 8 months maintenance (OTHER), Intervention plus 6 months maintenance (OTHER), Intervention plus 4 months maintenance (OTHER).
Who is sponsoring clinical trial NCT05051631?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05051631 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.